BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25194707)

  • 1. Brain tumours at 7T MRI compared to 3T--contrast effect after half and full standard contrast agent dose: initial results.
    Noebauer-Huhmann IM; Szomolanyi P; Kronnerwetter C; Widhalm G; Weber M; Nemec S; Juras V; Ladd ME; Prayer D; Trattnig S
    Eur Radiol; 2015 Jan; 25(1):106-12. PubMed ID: 25194707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla.
    Rumboldt Z; Rowley HA; Steinberg F; Maldjian JA; Ruscalleda J; Gustafsson L; Bastianello S
    J Magn Reson Imaging; 2009 Apr; 29(4):760-7. PubMed ID: 19306364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of a high relaxivity contrast agent administered at half dose in dynamic susceptibility contrast MRI of brain gliomas.
    Crisi G; Filice S; Erb G; Bozzetti F
    J Magn Reson Imaging; 2017 Feb; 45(2):500-506. PubMed ID: 27373976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children.
    Colosimo C; Demaerel P; Tortori-Donati P; Christophe C; Van Buchem M; Högström B; Pirovano G; Shen N; Kirchin MA; Spinazzi A
    Pediatr Radiol; 2005 May; 35(5):501-10. PubMed ID: 15678342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast lesion detection and characterization with contrast-enhanced magnetic resonance imaging: Prospective randomized intraindividual comparison of gadoterate meglumine (0.15 mmol/kg) and gadobenate dimeglumine (0.075 mmol/kg) at 3T.
    Clauser P; Helbich TH; Kapetas P; Pinker K; Bernathova M; Woitek R; Kaneider A; Baltzer PAT
    J Magn Reson Imaging; 2019 Apr; 49(4):1157-1165. PubMed ID: 30552829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Low-Dose Higher-Relaxivity and Standard-Dose Lower-Relaxivity Contrast Media for Delayed-Enhancement MRI: A Blinded Randomized Crossover Study.
    Cheong BY; Duran C; Preventza OA; Muthupillai R
    AJR Am J Roentgenol; 2015 Sep; 205(3):533-9. PubMed ID: 26295638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrast-enhanced MR imaging of hand and finger joints in patients with early rheumatoid arthritis: do we really need a full dose of gadobenate dimeglumine for assessing synovial enhancement at 3 T?
    Schueller-Weidekamm C; Lodemann KP; Grisar J; Schueller G; Weber M; Kainberger F; Platzgummer H
    Radiology; 2013 Jul; 268(1):161-9. PubMed ID: 23449952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Less is better? Intraindividual and interindividual comparison between 0.075 mmol/kg of gadobenate dimeglumine and 0.1 mmol/kg of gadoterate meglumine for cranial MRI.
    Khouri Chalouhi K; Papini GDE; Bandirali M; Sconfienza LM; Di Leo G; Sardanelli F
    Eur J Radiol; 2014 Jul; 83(7):1245-1249. PubMed ID: 24816087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain.
    Runge VM; Parker JR; Donovan M
    Invest Radiol; 2002 May; 37(5):269-80. PubMed ID: 11979153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations.
    de Campos RO; Heredia V; Ramalho M; De Toni MS; Lugo-Somolinos A; Fuller ER; Semelka RC
    AJR Am J Roentgenol; 2011 Mar; 196(3):545-52. PubMed ID: 21343495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast enhancement of brain tumors at different MR field strengths: comparison of 0.5 T and 2.0 T.
    Chang KH; Ra DG; Han MH; Cha SH; Kim HD; Han MC
    AJNR Am J Neuroradiol; 1994 Sep; 15(8):1413-9; discussion 1420-3. PubMed ID: 7985558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
    Knopp MV; Bourne MW; Sardanelli F; Wasser MN; Bonomo L; Boetes C; Müller-Schimpfle M; Hall-Craggs MA; Hamm B; Orlacchio A; Bartolozzi C; Kessler M; Fischer U; Schneider G; Oudkerk M; Teh WL; Gehl HB; Salerio I; Pirovano G; La Noce A; Kirchin MA; Spinazzi A
    AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of gadobenate dimeglumine vs gadopentetate dimeglumine in contrast- enhanced magnetic resonance imaging for diagnosis of solitary brain metastases].
    Wang QJ; Wang Y; Xu X; Xiao H; Ma L
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):1968-73. PubMed ID: 22200693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative and qualitative comparison of 0.025 mmol/kg gadobenate dimeglumine for abdominal MRI at 1.5T and 3T MRI in patients with low estimated glomerular filtration rate.
    Ramalho M; AlObaidy M; Busireddy KK; Altun E; Liu B; Semelka RC
    Eur J Radiol; 2015 Jan; 84(1):26-32. PubMed ID: 25467229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose contrast-enhanced magnetic resonance imaging of brain metastases at 3.0 T using high-relaxivity contrast agents.
    Huang B; Liang CH; Liu HJ; Wang GY; Zhang SX
    Acta Radiol; 2010 Feb; 51(1):78-84. PubMed ID: 19912078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model.
    Robert P; Vives V; Grindel AL; Kremer S; Bierry G; Louin G; Ballet S; Corot C
    Radiology; 2020 Jan; 294(1):117-126. PubMed ID: 31660804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
    Knopp MV; Runge VM; Essig M; Hartman M; Jansen O; Kirchin MA; Moeller A; Seeberg AH; Lodemann KP
    Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention.
    Kuhn MJ; Picozzi P; Maldjian JA; Schmalfuss IM; Maravilla KR; Bowen BC; Wippold FJ; Runge VM; Knopp MV; Wolansky LJ; Gustafsson L; Essig M; Anzalone N
    J Neurosurg; 2007 Apr; 106(4):557-66. PubMed ID: 17432704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T2*-Correction in Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Glioblastoma From a Half Dose of High-Relaxivity Contrast Agent.
    Filice S; Crisi G; Erb G
    J Comput Assist Tomogr; 2017; 41(6):916-921. PubMed ID: 28708734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.